SLC13A5 and chronic kidney disease: There were no strong associations of genetically proxied SLC13A5 inhibition with uACR (FDR adjusted p value = 0.682), or risk of CKD (FDR adjusted p value = 0.516) or microalbuminuria (FDR adjusted p value = 0.682).